Disclosure of Interests: None declared.


AB0056
cutaneous adverse effects with biologic agents

Bilal Bengana, Abdenour Boukabous, Naima Bahaz, Salima Lefkir. 
University of BeniMelssou, Rheumatology, ALGER, Algeria

Background: Biologic agents (BA) are designed to treat chronic inflammatory diseases (CID), however, the adverse effects inherent with these drugs are more and more encountered. Among them are dermatological manifestations: infections, allergic reactions or even skin cancers, which sometimes require stopping treatment temporarily or permanently.

Objectives: The goal of this work consists to identify the cutaneous manifestations (CA) that have been reported to the most commonly used biologics in CID.

Methods: It is a prospective study in patients received in day hospital and treated with BA for CID during a period of 9 months (October 2017 - June 2018), we collected all the data on CA after a complete dermatological examination, not forgetting that we appreciated the phototype of the patients, the level of exposure to the sun and means of photoprotection.

Results: We collected the data of 68 patients under BA for the study (Adalimumab = 21, Etanercept = 17, Tocilizumab = 12, Infliximab = 7, Rituximab = 11) with a clear female predominance 59.4%, the mean age was 39 years. 37 (54%) had cutaneous manifestations, the main CA occurred with TNFα treatments: use of corticosteroids p <0.0001, habitat in rural areas p= 0.042. 

Conclusion: Cutaneous manifestations remain frequent and relatively benign with BA. This work confirms the importance of education and dermatological monitoring of patients treated with biologic drugs in the CID. This prospective study needs to be completed over a longer period especially to screen any skin cancer.

Disclosure of Interests: None declared.


AB0057
assessmen of matrix metallopeptidase 3 (MMP3) as a potential biomarker for rheumatoid arthritis in Algerian patients

Mourina Benidi1, Samir Salahi2, Dalila Fodil2, Hachemi Djoudi2, Habiba Amroun3, Nabila Attal1, 1Pasteur Institute of Algeria, Immunology, Algiers, Algeria; 2Mustapha Dahmane Hospital, Immunology, Algiers, Algeria; 3Algerian Rheumatology, Algiers, Algeria

Background: Matrix metalloproteinase 3 (MMP3) is a protease induced by rheumatoid pannus pro-inflammatory cytokines during rheumatoid arthritis (RA) and degrades many cartilage and bone components. Its serum level is a useful marker for predicting joint destruction and evaluating disease activity.

Objectives: First, compare MMP3 production in RA patients to controls, then try to place this marker in the evaluation of disease activity.

Methods: We studied the blood of the studied patients in three groups:

• RA: n = 134; sex ratio: 1: 5; age: 50 ± 14 years; disease duration: 7 ± 9 years,
• Healthy controls: n = 67; sex ratio: 1: 7; age: 38 ± 11 years,
• Population control: Patients with:
  • Inflammatory rheumatism: n = 80,
  • Chronic inflammatory diseases (CID): 18 Connective tissue disease (CTD), 14 chronic hepatitis C and 2 Crohn disease (CD).

Susan Gilson, Debra S Floor, Linda S Darnell, Andrew P McGonagle; University of Manchester, Bone and Joint Research Group, Manchester, UK

Disclosure of Interests: None declared.


The serum MMP3 measurement was performed by ELISA assay.

**Results:** Serum MMP3 was significantly higher in RA patients vs. healthy controls (p < 0.0001). Inflammatory rheumatism (p < 0.0001) and CID (p < 0.05) and is particularly high in women with high Disease Activity Score 28 joints (DAS28) vs. Moderate DAS28 (p < 0.05). In addition, it is higher if patients have: positive CRP: p < 0.05; positive RF: p < 0.05; positive ACPA: p < 0.05 and Bone erosion: p < 0.01 compared to other patients. Finally, there is a positive correlation between MMP3 production and RF (p < 0.0001, Spearman r = 0.35) and ACPA (p < 0.01, Spearman r = 0.26) but not with DAS28 joining the results published by Mahmood et al (2013) and Fadda et al (2016). Furthermore, in RA patients, there is no significant difference in MMP3 levels according to whether the erythrocyte sedimentation rate (ESR) is accelerated or not, unlike CRP which represents the best marker of inflammation in this disease, according to the literature. Finally, the production of MMP3 is greater in case of erosion and is associated to bone and joint destruction.

**Conclusion:** MMP3 serum measurement is a particularly useful marker of inflammatory activity in RA and may have potential predictive value in the development of bone and joint destruction.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.8268

---

**SERUM OXYTOCIN LEVELS IN PATIENTS WITH AXIAL SPONDYLARTHRITIS**

Ozkan Yukselmis, Mehmet Caglayan, Pelin Oktayoglu, Nuriye Mete. Dicle University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Diyarbakir, Turkey; Dicle University Faculty of Medicine, Department of Biochemistry, Diyarbakir, Turkey

**Background:** Spondylarthropathy refers to a group of chronic inflammatory diseases with unknown etiologies that involve particularly sacroiliac joints and spine but may also affect the remaining joints and entheses and exhibit extra-articular involvement in some patients. Oxytocin is a peptide hormone released from hypothalamus and stored in pituitary gland. It has been known for a while that oxytocin is involved in some patients. Oxytocin is a peptide hormone released from hypothalamus and stored in pituitary gland. It has been known for a while that oxytocin has anti-inflammatory effects and can cause a reduction in TNF-alpha levels.

**Objectives:** The aim of this study was to investigate the serum levels of oxytocin and its potential association with disease activity, spinal mobility and some other laboratory parameters such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in patients with ankylosing spondylitis (AS) and non-radio-graphic axial spondyilitis (nrASpA).

**Methods:** Seventy-one patients with nrASpA and 38 patients with AS who presented to the Outpatient Clinic of Physical Medicine and Rehabilitation of Dicle University Hospital between March 2017-October 2017 and 67 healthy control subjects were included in this study. All the subjects underwent a thorough physical examination. Disease activity was assessed by Bath Ankylosing Spondylitis Disease Activity Index, and spinal mobility by Bath Ankylosing Spondylitis Metabolic Index. Laboratory examinations included complete blood count, ESR, CRP, and oxytocin tests.

**Results:** There was no significant difference in serum levels of oxytocin among the three groups (p = 0.973). However, serum levels of oxytocin correlated negatively with both ESR (-0.359, p = 0.027) and BASDAI (r = -0.448, p = 0.005) in patients with AS. On the other hand, serum levels of oxytocin had a negative correlation only with ESR in the patients with nrASpA (r = -0.321, p = 0.009).

**Conclusion:** ESR is one of the parameters associated with disease activity in patients with inflammatory rheumatoid diseases. Serum levels of oxytocin correlate negatively with both ESR and BASDAI scores in patients with AS and only with ESR in patients with nrASpA suggests that low levels of oxytocin may be associated with increased disease activity. This study lays the foundation for further studies that may aim to investigate how addition of oxytocin to the treatment regimen impact on the disease activity in patients with AS who exhibit particularly low levels of oxytocin during active disease period.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.3075

---

**AB0059**

**通过MAPK和NF-KB信号通路自体修饰药物抑制白细胞介素-37活性**

Xiaoyi Shi, Chunhui Liu, Lianyu Zhao, Mingying Zhang, Xi Lu, Shanpin Peng, Weizhong Guo, Song Chen, Guangqing Chen. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China

**Background:** Autophagy has been shown as an intrinsic cellular defense mechanism in innate and adaptive immune responses and is reported to regulate inflammation during infection [1]. Accumulating evidence indicates that autophagy suppresses inflammation [2-5]. IL-37 has been identified as an anti-inflammatory factor that translocates into the nucleus and downregulates other pro-inflammatory cytokines [6]. Nevertheless, whether autophagy regulates the expression of IL-37 has not been elucidated.

**Objectives:** The purpose of this study was to investigate the role of autophagy in regulating IL-37, an anti-inflammatory cytokine highly expressed in tissues of patients with inflammatory and autoimmune diseases.

**Methods:** PMA-transformed and LPS-stimulated U937 macrophages were treated with three autophagy-modulating reagents—3MA, chloroquine, and rapamycin. The expression of three IL-1 family cytokines (IL-37, IL-18, and IL-1β) and two receptors (IL-1R8 and IL-1R8A) was determined by quantitative PCR. Intra-cellular IL-37 expression was detected by flow-cytometry. Western blot analysis and immunofluorescence assay were used to determine the levels of P62/SQSTM1 and LC3, and autophagic U937 cells were isolated by sorting for quantifying IL-37 expression. We also used agonists and antagonists of the MAPK and NF-κB pathways to investigate the possible pathway involved. Peripheral blood mononuclear cells from one healthy donor were also used for autophagy modification and intracellular IL-37 quantitation.

**Results:** IL-37 was upregulated by rapamycin and chloroquine in U937 cells stimulated by LPS. IL-37 was preferentially expressed in autophagic cells accompanied with LC3 conversion. Higher IL-37 expression was found in “Cyto-ID” positive cells than in negative cells. Inductive IL-37 expression, but not constitutive IL-37 expression, could be abolished by inhibitors of the MAPK and NF-κB pathways, whereas it was augmented by MAPK agonists.

**Conclusion:** IL-37 levels were enhanced by rapamycin and chloroquine dependent on MAPK and NF-κB pathway activation, probably through LC3 accumulation. This study suggests a possible novel mechanism of chloroquine and rapamycin action in autoimmune inflammatory diseases.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.1045